Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Results suggest SSRIs enhance the efficacy of SPL026 when administered to MDD patients on a…
Cybin to acquire Small Pharma creating an international clinical-stage leader in novel psychedelic therapeutics.
Financial highlights and recent business and R&D highlights.
Mr. Peter Rands, co-founder and former CEO, has left his positions as an executive officer…
Preliminary findings from ongoing Phase I trial of SPL028 indicate potential for a unique therapeutic…
Multiple clinical milestones achieved with operational efficiencies underway.
5 new patent grants with 3 expected upcoming patent grants in May.
A highlight of recent news and events across April and May.
Dr. Carol Routledge will present a poster on our Phase IIa data.
A highlight of recent news and events so far.